scholarly journals The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes

2020 ◽  
Vol 22 (12) ◽  
pp. 2451-2459 ◽  
Author(s):  
Jonathan M. Wilson ◽  
Amir Nikooienejad ◽  
Deborah A. Robins ◽  
William C. Roell ◽  
Jeffrey S. Riesmeyer ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
Receptor Agonist ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Insulinotropic Peptide

938-P: The Relationship between Timing of Initiation on a Glucagon-Like Peptide-1 Receptor Agonist and HbA1c among Patients with Type 2 Diabetes

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 938-P
Author(s):  
RALEIGH E. MALIK ◽  
REEMA MODY ◽  
MAUREEN J. LAGE ◽  
KRISTINA BOYE
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Agonist ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Timing Of Initiation ◽  
The Relationship

scholarly journals Glucagon-Like Peptide 1 Receptor Agonist (GLP1RA) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies

2021 ◽  
Author(s):  
Thomas M. Caparrotta ◽  
Jack B. Templeton ◽  
Thomas A. Clay ◽  
Sarah H. Wild ◽  
Rebecca M. Reynolds ◽  
...  
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
Observational Studies ◽  
Receptor Agonist ◽  
Population Based ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Co-Purification of Recombinant Modified Glucagon-Like and Glucose-Dependent Insulinotropic Peptide to Create a Two-Component Drug for the Treatment of Type 2 Diabetes Mellitus and Obesity

2021 ◽  
Vol 37 (6) ◽  
pp. 74-83
Author(s):  
A.Yu. Gorbunova ◽  
E.P. Sannikova ◽  
I.I. Gubaidullin ◽  
O.M. Ignatova ◽  
M.Yu. Kopaeva ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Mouse Model ◽  
Specific Activity ◽  
Two Component ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Insulinotropic Peptide

In addition to the previously developed recombinant modified human glucagon-like peptide 1 (rmglp1, Glypin), a recombinant modified human glucose-dependent insulinotropic peptide (RMGIP) has been obtained. A new universal reverse-phase HPLC technique has been proposed allowing quantitative analysis of rmGlp1 and rmGip separately and as part of a two-component preparation. The data show that the design of recombinant human rmGip according to the Glypine formula makes it possible to produce one-component and two-component preparations containing various rmGip and rmGlp1 protein ratios ranging from 1:0 to 20:1, using cell biomass samples mixed in predetermined proportions. Studies of human rmGip activity in a mouse model revealed reduced specific activity and signs of weak antagonistic effects. In this regard, there is a need for further study of human rmGip activity in a mouse model, including the use of alternative mouse or rat rmGip. type 2 diabetes mellitus; two-component drug, glucose-dependent insulinotropic peptide, glucagon-like peptide-1 The work was supported by the Internal Grant from National Research Center Kurchatov Institute.

scholarly journals Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?

2018 ◽  
Vol 36 (2) ◽  
pp. 138-147 ◽  
Author(s):  
Vanita R. Aroda ◽  
Joseph R. Arulandu ◽  
Anthony J. Cannon
Keyword(s):  
Type 2 Diabetes ◽  
Combination Therapy ◽  
Receptor Agonist ◽  
Two Agents ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Better Than

scholarly journals Potential cardiovascular benefits of GLP-1 analogues: evidence and implications for type 2 diabetes management

2020 ◽  
pp. 24-29
Author(s):  
M Vally
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
Paradigm Shift ◽  
Diabetes Management ◽  
Clinical Trial Data ◽  
Sglt2 Inhibitors ◽  
Atherosclerotic Cardiovascular Disease ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Glucagon-like peptide-1 (GLP-1) analogues are an injectable therapy used in the management of type 2 diabetes. These drugs seem to reduce cardiovascular risk factors and clinical trial data seems to suggest that liraglutide and semaglutide reduce cardiovascular risk in patients with type 2 diabetes and concomitant atherosclerotic cardiovascular disease. The search for agents such as these (and SGLT2 inhibitors) that not only manage diabetes but also reduce cardiovascular risk has resulted in a paradigm shift in the way diabetes can be managed.

The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials

2019 ◽  
Vol 154 ◽  
pp. 101-115 ◽  
Author(s):  
Maria Ida Maiorino ◽  
Paolo Chiodini ◽  
Giuseppe Bellastella ◽  
Lorenzo Scappaticcio ◽  
Miriam Longo ◽  
...  
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
Randomized Controlled Trials ◽  
Receptor Agonist ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1
Sign in / Sign up

Export Citation Format

Share Document